The implementation of pharmacogenomic (PGx) testing in psychiatry remains modest, in part
due to divergent perceptions of the quality and completeness of the evidence base and …

ABSTRACT Introduction: Adverse drug reactions (ADRs) are a major health concern
worldwide. There are multiple causes of ADRs, some of which are preventable …

Aim: To conducted a systematic review and meta-analysis of prospective, randomized
controlled trials (RCTs) that examined pharmacogenetic-guided decision support tools …

On the basis of evidence base, we proposed a minimum gene and allele set for
pharmacogenetic testing in psychiatry that includes 16 variant alleles within five genes …

Purpose The development and implementation of a multidisciplinary pharmacogenomics
clinic within the framework of an established community-based medical genetics program …

Background PGx is the understanding and extrapolation of variations in the patient's
underlying DNA into therapeutic recommendations or more simply use of a patient's specific …

Clinical genetic testing began over 30 years ago with the availability of mutation detection
for sickle cell disease diagnosis. Since then, the field has dramatically transformed to …

Purpose: Dramatic advances in genomic technology stand to revolutionize cancer care;
however, little is known about patients' understanding and acceptance of personalized …

Precision medicine has grown over the past 20 years with the availability of genetic tests
and has changed the one‐size‐fits‐all paradigm in medicine. Precision medicine …

Background: Thousands of biomarker tests are either available or under development for
lung diseases. In many cases, adoption of these tests into clinical practice is outpacing the …